Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
about
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian childrenInduction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsImmunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunizedImproving malaria control in West Africa: interruption of transmission as a paradigm shift.Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine.A new malaria antigen produces partial protection against Plasmodium yoelii challengeProgress and prospects for blood-stage malaria vaccinesProphylactic and therapeutic implications of toll-like receptor ligands.Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
P2860
Q28740701-053FAF2B-2A9E-4EAF-AD91-05F06D355AC3Q28741242-EF278590-8D56-4049-9E65-BF2635DEBEF5Q28743092-6E0D253F-DF0F-4145-BD1A-A115C7BFBCDCQ28744573-DB8B09B5-EDAB-48A4-8866-9AE0CDE5C189Q28972540-14E1B46D-D6A4-4AF0-98D0-A5484F3D7670Q33521372-B8E80CBD-541B-40F5-9A36-124287F3BD95Q34043843-F12DF5B4-E50F-4C45-8F4A-12889B5011AAQ34546208-A6C559C2-2091-417B-A07D-B18D9BD1D8D5Q34612788-9A0C0CBF-C942-4AB3-B8D0-77DF24A31D81Q35803321-4834CF45-9CD7-4F13-AADE-513C18EC6C66Q35867612-72080C7E-D597-4039-97E1-896DA718D6D0Q36219507-11DD9172-D549-4CFE-B042-59E161BAC6B1Q37025030-8D15351E-7003-4C40-81AB-0A8FB668896FQ37989884-BAA1A4DA-79FE-41AF-AF25-5F2701AF3503Q38599514-839CC14A-6582-4A3E-B3CB-B50AA87D032A
P2860
Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Five-year safety and immunogen ...... -endemic region of The Gambia.
@en
type
label
Five-year safety and immunogen ...... -endemic region of The Gambia.
@en
prefLabel
Five-year safety and immunogen ...... -endemic region of The Gambia.
@en
P2093
P2860
P50
P356
P1433
P1476
Five-year safety and immunogen ...... -endemic region of The Gambia.
@en
P2093
Amanda Leach
Kent Kester
Kurt Schaecher
Marc Lievens
Opokua Ofori-Anyinam
Tom Doherty
P2860
P304
P356
10.4161/HV.5.4.7050
P577
2009-04-22T00:00:00Z